Market capitalization | $708.49m |
Enterprise Value | $315.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.66 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-238.46m |
Free Cash Flow (TTM) Free Cash Flow | $-192.93m |
Cash position | $469.12m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Replimune Group, Inc. forecast:
10 Analysts have issued a Replimune Group, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.79 -2.79 |
24%
24%
|
|
EBITDA | -236 -236 |
24%
24%
|
EBIT (Operating Income) EBIT | -238 -238 |
23%
23%
|
Net Profit | -220 -220 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Head office | United States |
CEO | Sushil Patel |
Employees | 331 |
Founded | 2015 |
Website | www.replimune.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.